Drug prices in Russia to grow by 20% this year, despite state control

9 February 2015
moscow-big

Drug prices in Russia may increase by 20% this year, according to a recent statement of Russia’s Prime Minister Dmitry Medvedev during his visit to Ufa.

Mr Medvedev explained: "Unfortunately, we face with an increase in the cost of drugs. In some regions, the growth has already exceeded 15%, compared to the same period of last year. According to experts, this year drug prices could rise by 20%. This is partly due to exchange rate fluctuations. However this is also the result of recent speculations."

He has added that the government carries out a special control for the prices for vital and essential drugs, the list of which was recently expanded. Mr Medvedev said that the government will do everything in order to prevent pushing out cheap drugs from the market. As part of these plans, the government will allow only a one-time indexation of prices for vital and essential drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical